HIMS Stock Analysis — Hims & Hers Health
Sector: Healthcare
AI Verdict
You're paying up for a narrative of sticky, high-growth telehealth — unless HIMS keeps compounding above 30% and proves out its moat, the price is expensive for the earnings delivered so far.
Competitive Moat
Hims & Hers Health operates a direct-to-consumer telehealth platform focused on stigmatized conditions like hair loss and sexual health, leveraging a brand-driven, vertically integrated model. Its defensibility comes from a sticky customer base and regulatory know-how in online prescription fulfillment, making it hard for generic telehealth competitors to replicate the same trusted consumer experience at scale.
Summary
Hims is notable for its rapid 32.8% revenue growth as it expands its digital health subscription base.
Where It Stands
HIMS trades at a trailing P/E of 61.2x, nearly triple the healthcare sector median of 22x, while delivering 32.8% revenue growth year-over-year.
Key Metrics
- Trailing P/E: 61.2x
- Revenue Growth: +0.3%
- 52-Week High: $70.43
- 52-Week Low: $13.74
Analyst Consensus
10 Buy · 13 Hold · 0 Sell (23 analysts)
Bull Case
A 32.8% revenue growth rate supports a premium multiple if HIMS maintains its pace and customer retention.
Bear Case
If the P/E multiple compresses from 61.2x to the sector median of 22x, the stock could lose nearly two-thirds of its value unless earnings growth accelerates sharply.
Catalyst to Watch
Watch for quarterly subscriber retention and margin expansion — a miss on either could quickly deflate the high multiple.